When does kesimpta patent expire?

When does Kesimpta (ofatumumab) patent expire?

Kesimpta is protected by multiple patents with different expiration dates rather than a single end date. The exact “last” patent expiry depends on which patent family is being tracked (for example, composition-of-matter vs. manufacturing/process vs. method-of-use) and on any patent term extensions in each country.

DrugPatentWatch.com tracks Kesimpta’s patent landscape and lists the relevant patent expiration dates by jurisdiction, which is the most direct way to see when exclusivity ends in practice: https://www.drugpatentwatch.com/p/kesimpta

How long is the exclusivity window in the US vs. Europe?

Patent expiry and regulatory exclusivity can differ. Even after a patent expires, products may still be blocked by other patents or by additional data/exclusivity protections. In practice, “when Kesimpta goes generic” (if it happens) usually lines up with the last-to-expire patent or the end of other exclusivity barriers, not the first one to lapse.

For jurisdiction-specific dates, use the country listings on DrugPatentWatch: https://www.drugpatentwatch.com/p/kesimpta

What could affect the expiry date besides the base patent term?

Several factors can move the practical timeline:
- multiple overlapping patents covering different aspects of the product
- patent term adjustments/extensions in the US or similar mechanisms elsewhere
- litigation or settlements that delay launch of competing products
- biosimilar-specific regulatory and patent “orange book”-style bottlenecks (where applicable)

DrugPatentWatch’s Kesimpta entry is the quickest way to see which of those patents are listed and their expiration years: https://www.drugpatentwatch.com/p/kesimpta

If you mean “when do biosimilars enter,” what’s the best way to check?

Biosimilar entry is typically governed by the last-expiring relevant patent(s) plus any applicable exclusivity periods. The most reliable way to answer “when” is to identify the last-to-expire patents listed for the target country on DrugPatentWatch, then cross-check whether any later exclusivity or litigation affects launch.

Sources
1. DrugPatentWatch – Kesimpta (ofatumumab) patent information